Study identifier:D589DL00001
ClinicalTrials.gov identifier:NCT01713075
EudraCT identifier:N/A
CTIS identifier:N/A
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for long-term use for COPD patients
Chronic Obstructive Pulmonary Disease
-
No
-
All
1183
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2018 by AstraZeneca
AstraZeneca
-
The purpose of the investigation is to confirm the safety and efficacy in long-term use of Symbicort Turbuhaler in patients with Chronic obstructive pulmonary disease (COPD) under the post-marketing actual use.
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for long-term use for COPD patients
Arms | Assigned Interventions |
---|---|
Symbicort | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.